^
Association details:
| Biomarker: | ESR1 wild-type + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Guideline and Rapid Update
Published date:
03/23/2023
Excerpt:
For patients with prior CDK4/6 inhibitor treatment and ESR1 wildtype tumors, appropriate subsequent ET options include fulvestrant, aromatase inhibitor monotherapy, other older ET options such as tamoxifen, or ET in combination with targeted agents such as alpelisib (for PIK3CA mutated tumors), or everolimus.
